"Carry-Over" Effect of CDK4/6 Inhibitors in Adjuvant Therapy for Hormone Receptor (HR)-Positive/HER2-Negative Early Breast Cancer: Clinical Evidence and Molecular Approach. This evidence concerns the gene CDK4 and breast cancer.